Abstract:Immunotherapy has emerged as a pioneering therapeutic modality, particularly within the realm of oncology, where Chimeric Antigen Receptor T-cell (CAR-T) therapy has manifested significant efficacy in the treatment of hematological malignancies. Nonetheless, the extension of immunotherapy to solid tumors poses a considerable challenge. This challenge is largely attributed to the intrinsic "cold" characteristics of certain tumors, which are defined by scant T-cell infiltration and a diminished immune response. Additionally, the impediment is exacerbated by the elusive nature of numerous targets within the tumor microenvironment, notably those deemed "undruggable" by small molecule inhibitors. This scenario underscores an acute necessity for the inception of innovative therapeutic strategies aimed at countering the resistance mechanisms underlying immune evasion in cold tumors, thereby amplifying the efficacy of cancer immunotherapy. Among the promising strategies is the deployment of Proteolysis Targeting Chimeras (PROTACs), which facilitate the targeted degradation of proteins. PROTACs present unique advantages and have become indispensable in oncology. However, they concurrently grapple with challenges such as solubility issues, permeability barriers, and the classical Hook effect. Notably, advanced delivery systems have been instrumental in surmounting these obstacles. This review commences with an analysis of the factors contributing to the suboptimal responses to immunotherapy in cold tumors. Subsequently, it delivers a thorough synthesis of immunotherapeutic concepts tailored for these tumors, clarifying the integral role of PROTACs in their management and delineating the trajectory of PROTAC technology from bench-side investigation to clinical utilization, facilitated by drug delivery systems. Ultimately, the review extrapolates the prospective future of this approach, aspiring to present novel insights that could catalyze progress in immunotherapy for the treatment of cold tumors.

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

[Advances in targeted delivery of proteolysis targeting chimeras in cancer therapy]

Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future

PROTACs: Current and Future Potential as a Precision Medicine Strategy to Combat Cancer

PROTAC delivery in tumor immunotherapy: Where are we and where are we going?

Small-Molecule PROTACs for Cancer Immunotherapy

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Engineering POLYTAC Nanoparticles for Bioorthogonal Click Reaction-Enforced Protein Degradation and Breast Cancer Therapy

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

New-generation advanced PROTACs as potential therapeutic agents in cancer therapy

PROTACs: A novel strategy for cancer therapy

New Generation of PROTACs: Advancement in Light‐Responsive and Self‐Assembled PROTACs

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Enhanced Tumor Targeting and Penetration of Proteolysis-Targeting Chimeras Through Irgd Peptide Conjugation: A Strategy for Precise Protein Degradation in Breast Cancer.

Developments of PROTACs technology in immune-related diseases

Recent Advances in Pro-PROTAC Development to Address On-Target Off-Tumor Toxicity.

Development of PROTAC Degrader Drugs for Cancer

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Recent Advances in Small Molecule PROTACs for the Treatment of Cancer